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a,b JordanObjectives: To assess the effectiveness of corticosteroids in the prophylaxis of postoperative atrial fibrillation (AF) in
patients undergoing elective coronary artery bypass grafting or valvular heart surgery in terms of reducing its incidence
and decreasing the length of hospital stay.
Methods: This prospective double blinded randomized study was conducted at Queen Alia Heart Institute
(Amman, Jordan) from June 2014 to June 2015 on 340 patients who underwent their first on-pump elective coronary
artery bypass grafting (CABG) alone or combined with valvular surgery. Inclusion criteria consisted of elective first
time CABG or combined with valvular surgery, use of b-adrenergic blockade, and normal sinus rhythm. Exclusion
criteria included a history of heart block, previous episodes of AF or flutter, uncontrolled diabetes mellitus, history
of peptic ulcer disease, systemic bacterial or mycotic infection, permanent pacemaker, and any documented or sus-
pected supraventricular or ventricular arrhythmias. Patients were randomized into two equal groups (n = 170 each),
then each group was subdivided into patients who underwent CABG alone (n = 120), and patients underwent valvu-
lar heart surgery with or without CABG (n = 50). In the treatment group, patients were given 1 g of methylpred-
nisolone before cardiopulmonary bypass then 100 mg of hydrocortisone every 8 hours for the first 3 days
postoperatively. The primary endpoint was the overall occurrence of postoperative AF.
Results: AF developed in 21.1% (36 patients) in the treatment group in contrast to 38.2% (65 patients) in the control
group (p < 0.05). In the subdivided groups (CABG only), approximately 20% (24 patients) developed AF in the treat-
ment group in contrast to 35% (42 patients) in the control group (p < 0.05). In the other group, (CABG + VALVE) 24%
(12 patients) developed AF compared with 46% (23 patients) in the control group (p < 0.05). The length of hospital
stay was 6.02 þ 11.23 days in the treatment group while it was 5.98 þ 1.86 days in the control group, which was found
to be statistically nonsignificant. No statistical significant difference in the rate of postoperative complications
including mediastinitis as well superficial wound infections was observed between the two groups.
Conclusion: Prophylactic short-term use of steroids both intraoperatively and postoperatively proved to be safe
and effective in reducing the incidence of postoperative AF in patients undergoing CABG alone or combined with
valve surgery.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
AF atrial fibrillation
CABG coronary artery bypass grafting
CPB cardiopulmonary bypass
LA left atrium
GIT gastrointestinal
CRP creactive protien
COPD chronic obstructive lung disease
RCTs randomized controlled trials
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Coronary artery bypass grafting (CABG) usingcardiopulmonary bypass triggers general-
ized response characterized by leukocyte and
complement activation, high levels of C-reactive
protein (CRP) complexes, as well high levels of
inflammatory mediators [1–3]. These mediators,
such as interleukins-6 and -8, tumor necrosis fac-
tors, leukotriene B4, and tissue plasminogen acti-
vator, might contribute to many postoperative
complications including atrial fibrillation (AF),
myocardial ischemia, multiorgan dysfunction,
and infections [1–4]. This is because those sub-
stances have known cardiodepressant effects [5].
AF is the most common postoperative complica-
tion with incidence of 20–50% following CABG
[1,3] and even higher after CABG and valve sur-
gery in up to 40–50% [1]. It commonly occurs at
0–4 days [6,7] with the peak incidence on the 2nd
to 3rd postoperative day [7–9]. AF is associated
with hemodynamic instability, increased risk of
thromboembolism and stroke, prolonged hospi-
talization and increased morbidity with conse-
quent high costs [1,2,10,11].
Many drugs have been used to decrease the
likelihood of developing AF, including b-
adrenergic blockers, amiodarone, and magnesium
[3,12].
Because of the known physiologic effects of ster-
oids to suppress the release of the above men-
tioned inflammatory mediators, steroids might
have beneficial effects in decreasing postoperative
AF, and inhibiting the inflammatory process post-
cardiopulmonary bypass [1,3,5]. Moreover, they
decrease capillary wall permeability, preventing
migration of inflammatory mediators into the sys-
temic circulation [5]. However, much debate exists
regarding their protective effects in relation to the
well-known side effects such as hyperglycemia,
gastrointestinal disturbances, and postoperative
infection [1,5].
The purpose of this study is to assess the use of
short-term steroids in the prophylaxis of AF in
patients undergoing elective CABG or combined
CABG and valvular heart surgery.Methods
This was a prospective randomized controlled
study that was conducted at Queen Alia Heart
Institute (Amman, Jordan) between June 2014
and June 2015. The study protocol was approved
by the Jordanian royal medical services localethical committee. There were 340 consecutive
patients scheduled to undergo their first on-
pump CABG, or combined CABG and valvular
surgery enrolled in this study. A total of 865
patients were screened with 516 excluded from
the study as well nine patients who refused to
be enrolled in the study.
Inclusion criteria consisted of elective first time
CABG or combined with valvular surgery, use of
b-adrenergic blockade, and normal sinus rhythm.
Exclusion criteria included: a history of heart
block; previous episodes of AF or flutter; uncon-
trolled diabetes mellitus; history of peptic ulcer
disease; systemic bacterial or mycotic infection;
permanent pacemaker; any documented or sus-
pected supraventricular or ventricular arrhyth-
mias; urgent or emergency surgery; if the patient
underwent cardiac surgery without using car-
diopulmonary bypass; and renal insufficiency
(serum creatinine >20 mg/dL).
The study’s primary end point was the occur-
rence of an episode of AF lasting P30 minutes or
hemodynamic instability due to AF regardless of
episode duration during the first 96 hours after
cardiac surgery. Secondary end points were the
length of hospital stay and the adverse effects of
steroids. We followed up the patients during the
first 2–4 weeks after surgery to check for wound
infection, therefore, patient charts were ordered
for verification. In addition, the patient charts
were checked 6 months after the surgery to assess
the incidence of major postoperative complica-
tions (mediastinitis or other complications requir-
ing hospitalizations).
All patients in the hydrocortisone and placebo
groups underwent the complete protocol of the
intended treatments until designated end points,
so intention was the same as treatment. After the
first episode of AF, the study protocol was
discontinued.
Patients underwent cardiac surgery on standard
cardiopulmonary bypass. Intermittent blood or
cold cardioplegia solution was administered via
the antegrade or retrograde route. The cardiople-
gia solution consisted of 32 meq/dL of magnesium
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istered. No steroids were included in the perfu-
sion protocol.
The age, history of hypertension or diabetes
mellitus, total pump time and aortic cross clamp
time, time onset of AF, and hospital stay duration
were recorded. The protocol was double-blinded,
in which the surgical staff, principal investigators,
and patients were blinded to the assigned ther-
apy; clinical data were collected and recorded
in the database by independent blinded
investigators.
Randomization lists were sent to the department
of pharmacy, where study drugs were prepared.
The investigator sent the name and date of birth
each time a new patient had given written
informed consent. Randomization was performed
on the operation day. The pharmacist selected the
next number on the randomization list, labelled
the drug container with the patient’s name, and
sent the container to the department where the
patient was treated. The study group remained
unknown to all caring nurses and physicians.
The randomization codes were opened after the
end of study. The study drugs were prepared in
our center’s department of pharmacy under asep-
tic technique. Both the active drug and the pla-
cebo preparations were identical regarding color
and other characteristics.
All patients who were randomized into either
the study or control group, had normal sinus
rhythm prior to surgery.
Patients were divided into two major equal
groups, each including 170 patients: i.e., the ster-
oid group and the saline (control) group. Then
each group was subdivided into patients undergo-
ing isolated CABG (n = 120), and patients under-
going valve surgery with or without CABG
(n = 50).
Patients were randomly assigned in a double-
blind fashion either to a placebo group receiving
maintenance fluids (5% dextrose water withTable 1. Characteristics of the patient groups.
Characteristics Placebo
(n = 170)
Age (y) 64.2 ± 8.9
Male 89 (52.3)
Female 81 (47.7)
Hypertension 93 (54.7)
Diabetes 53 (31.1)
History of COPD 11 (6.4)
Preoperative use of b-blockers 141 (82.9)
Unstable angina 33 (19.4)
Data are presented as n (%) or mean ± SD.
COPD = chronic obstructive pulmonary disease; NS = not significant; SD = spotassium chloride 20 meq/L) or to a steroid
group receiving 1 g of intravenous methyl pred-
nisolone sodium succinate before cardiopul-
monary bypass, and then 100 mg hydrocortisone
every 8 hours for the next 3 days. Patients received
the usual postoperative cardiac care including b
blockade to prevent atrial arrhythmias.
Patients stopped receiving either choice if AF
occurred. Regarding general anesthesia, surgical
techniques and patient monitoring were stan-
dardized for all patients.
Patients were continuously monitored in the
cardiac surgery intensive care unit with arterial
and central venous monitoring. Cardiac rhythm
was continuously monitored in the intensive care
unit using bed side monitors and telemetry in
the ward. The ward monitors stored 24-hour elec-
trocardiographic recordings for subsequent analy-
sis and 12 lead electrocardiographic recordings
were performed if necessary to confirm the
rhythm.
Values are presented as means ± standard devi-
ation and percentages. Chi-square was used to
analyze the results, differences were considered
to be statistically significant when p < 0.05. The
test was used for comparison of patients in terms
of duration of hospitalization.Results
The demographic data did not differ signifi-
cantly between the two groups as the groups were
well matched.
The age of the treatment and control group were
comparable (64.2 ± 8.9 years vs. 65.7 ± 9.2 years) as
was the sex (52.3% men vs. 50.5% men). Hyperten-
sion was found in 54.7% (93 patients) of the pla-
cebo group and in 52.3% (89 patients) of the
treatment group. Diabetes was found in 31.1%
(53 patients) of the placebo group and in 32.3%
(55 patients) of the treatment group. No statistical
significance was found between the two groups inHydrocortisone
(n = 170)
Univariate p
65.7 ± 9.2 NS
86 (50.5) NS
84 (49.5) NS
89 (52.3) NS
55 (32.3) NS
13 (7.6) NS
147 (87) NS
35 (20.5) NS
tandard deviation.
Table 2. Perioperative characteristics of the patient groups.
Characteristics Placebo
(n = 170)
Hydrocortisone
(n = 170)
Univariate p
Type of surgery
Isolated CABG 120 (70.5) 120 (70.5)
Combined CABG and valve 50 (29.5) 50 (29.5)
Total pump time (min) 102.5 ± 22.32 103.6 ± 21.85 NS
Aortic cross clamp (min) 55.62 ± 13.82 54.82 ± 14.20 NS
Development of atrial fibrillation 65 (38.2) 36 (21.17) < 0.001
CABG group (n = 120) 42 (35) 24 (20) < 0.05
CABG + valve (n = 50) 23 (46) 12 (24) < 0.05
Data are presented as n (%) or mean ± SD.
CABG = coronary artery bypass graft; NS = not significant; SD = standard deviation.
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chronic obstructive pulmonary disease. Preopera-
tive characteristics are shown in Table 1.
Mean aortic cross clamp time in the placebo
group was 55.62 ± 13.82 minutes versus
54.82 ± 14.20 minutes in the treatment group. The
total pump time was found to be 102.5 ± 22.32 min-
utes in the placebo group versus 103.6 ± 21.85
minutes in the treatment group. Both parameters
were found to be statistically nonsignificant
(p > 0.05; Table 2).
The incidence of postoperative AF was found to
be 21.17% in the hydrocortisone group (36 patient
developed AF) versus 38.2% (65 patients devel-
oped AF) in the placebo group (Fig. 1).
When dividing the patients into those who
underwent CABG only and those who underwentRandomiz
n = 340
Hydrocortisone group
n =  170
Valve and CABG
50
CABG only 
120
12 patients AF 
(24%)
24 patients AF 
(20%)
Figure 1. Summary of the study results. AF = atrial fivalve surgery with or without CABG, the inci-
dence of AF in the CABG group was 20% (24
patients) in the hydrocortisone group while it
was 35% (42 patients) in the placebo group
(p < 0.05). By contrast, in the CABG and valve
group the incidence of AF in the hydrocortisone
group was 24% (12 patients) in comparison to
46% (23 patients) in the placebo group (p < 0.05).
It was seen that the incidence of AF was higher
in the valve patients than the CABG group with
or without hydrocortisone treatment, which is
due partly to the effect of valve pathology.
Serum potassium and magnesium levels were
not found to be statistically significant between
the two groups, which excludes any electrolyte
disturbances as potential cause for the signifi-
cance difference in development of AF. However,ed
placebo group
n = 170
CABG and Valve
50
CABG only 
120
23 patients AF 
(46%)
42 patients AF 
(35%)
brillation; CABG = coronary artery bypass graft.
Table 3. Postoperative characteristics of the patient groups.
Characteristics Placebo
(n = 170)
Hydrocortisone
(n = 170)
Univariate p
Onset of AF (h after operation) 22.4 ± 23.5 18 ± 22.6 NS
In hospital AF 65 (38.2) 36 (21.17) < 0.001
Mortality during study period 2 (1.17) 2 (1.17) NS
Perioperative MI 3 (1.76) 2 (1.17) NS
Upper GIT bleeding 6 (3.5) 7 (4.1) NS
Postoperative mediastinits 2 (1.17) 3 (1.76) NS
Superficial wound infection 9 (5.29) 11 (6.4) NS
High blood sugar 7 (4.1) 13 (7.6) NS
Serum potassium level before AF (meq/L) 4.3 ± 0.29 4.2 ± 0.35 NS
Serum magnesium level before AF (meq/dL) 1.7 ± 0.32 1.8 ± 0.29 NS
Postoperative CRP level (mg/L)
1st day 65.1 ± 28.2 51.1 ± 24.8 < 0.05
2nd day 171.2 ± 45.2 102.3 ± 35.2 < 0.05
3rd day 183.2 ± 50.2 97.2 ± 40.2 < 0.05
Length of hospital stay (d) 5.95 ± 1.95 6.02 ± 2.25 NS
Left atrial chamber size (units) 4.5 ± 1.7 4.7 ± 1.6 NS
Data are presented as n (%) or mean ± SD.
AF = atrial fibrillation; CRP = C-reactive protein; GIT = gastrointestinal; MI =myocardial infarction; NS = not significant; SD = standard deviation.
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SHORT-TERM STEROIDS FOR ATRIAL FIBRILLATIONthe concentration of CRP on the 1st, 2nd, and 3rd
postoperative days were significantly lower in
the hydrocortisone group than in the placebo
group (Table 3) which might explain the anti-
inflammatory effects of steroids on patients post-
cardiopulmonary bypass. No statistical difference
was found in left atrium (LA) size between the
two groups, which exclude this factor as potential
cause for increased risk of developing AF.
There were no statistically significant differ-
ences between the two groups with respect to
mediastintis, superficial wound infections, upper
gastrointestinal bleeding, and overall mortality.
However, it was noticed that blood sugar levels
were higher in the hydrocortisone group, but with
no statistical significance.
With regard to the distribution of valvular oper-
ations performed, aortic valve replacement is the
commonest followed by mitral valve replacement
(see Table 4).Table 4. Distribution of operations performed.
Type of surgery n Percentage (%)
CABG + AVR 5 10
AVR 14 28
MVR 11 22
CABG + MVR 6 12
AVR +MVR 5 10%
MVR + TVR 7 14%
AVR +MVR + TVR 2 4%
AVR = aortic valve replacement; CABG = coronary artery bypass graft-
ing; MVR =mitral valve replacement; TVR = tricuspid valve repair.Discussion
Prophylactic short-term steroids given in
patients undergoing CABG reduced the occur-
rence of postoperative AF by approximately 50%
[3]. In our study, it was found to be approximately
45% decreased risk of developing AF in patients
undergoing isolated CABG and CABG combined
with valve surgery, which is close to the landmark
work of Halonen et al. [2], who conducted a
prospective, double-blind, randomized multicen-
ter trial of the effect of 100 mg hydrocortisone
given intravenously every 8 hours for 3 days post-
operatively. They found 37% risk reduction in the
development of AF in the group who received
hydrocortisone compared with the control group.
In this study, the incidence of AF was significantly
lower in the hydrocortisone group (30% vs. 48%;
p = 0.004).
The mechanism behind the beneficial effects of
hydrocortisone on the development of AF is not
well known [2]. Direct effects of steroids, such as
reduction in proinflammatory cytokine release,
slowed leukocyte migration, and decreased capil-
lary leak have been proposed as possible mecha-
nisms [3,13–16]. Moreover, Halonen et al. [2]
found a significant decrease in CRP levels in the
group who received hydrocortisone. Hence, this
might support the inflammatory etiology of post-
operative AF. A study by Dernellis and Panaretou
[17] also found that corticosteroid therapy reduces
the CRP values and the risk of recurrent and per-
manent AF in nonoperative patients. Another pos-
sible effect of steroids is the antiemetic effect with
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medications such as b-blockers with resulting
reduction in the incidence of AF [2].
Concerning the risk analysis of postoperative
AF, we found that the older age group, chronic
obstructive pulmonary disease patients, male
sex, valve surgery, and longer cross clamp time,
were significant predictors of AF development.
After adjusting the above-mentioned factors, cor-
ticosteroid administration was found to be a sig-
nificant independent predictor of absence of AF.
Yared et al. [18] found the same result of a lower
incidence of new-onset AF with the administra-
tion of dexamethasone 0.6 mg/kg after induction
of anesthesia. They found that patients receiving
dexamethasone had a lower incidence of AF dur-
ing the first 3 days postoperatively (18.9% vs.
32.3%; p = 0.02). Prasongsukarn et al. [3] enrolled
88 patients in their randomized controlled study
(43 patients received 1 mg of methylprednisolone
before surgery and 4 mg of dexamethasone every
6 hours for 1 day after surgery). They found that
AF occurred in 9 (21%) patients in the steroid
group and 22 (51%) patients in the placebo group
(p = 0.003).
Ho and Tan [19] analyzed 50 randomized con-
trolled trials including 3323 patients and found
that corticosteroids prophylaxis reduced the risk
of postoperative AF (25.1% vs. 35.1%). With regard
to the dose-related effects of hydrocortisone on
postoperative AF, Marik and Fromm [20] found
that moderate doses of hydrocortisone equiva-
lents (200–1000 mg/d) should be considered for
the prevention of AF in high risk patients under-
going cardiac surgery. Furthermore, Ho and Tan
[19] found that low-dose corticosteroid is as effec-
tive as high-dose corticosteroid in reducing the
risk of AF and mechanical ventilation but with
fewer potential side effects in adult cardiac sur-
gery; i.e., no additional benefits were found on
all outcomes beyond a total dose of 1000 mg
hydrocortisone. Nevertheless, the study by Hal-
vorsen et al. [21] showed that dexamethasone
(4 mg of dexamethasone or placebo after induc-
tion of anesthesia and on the 1st postoperative
day in 300 patients undergoing CABG) was bene-
ficial in reducing emetic symptoms and improving
appetite after cardiac surgery but had no effect on
the occurrence of postoperative AF. This may be
related to the different doses of corticosteroids
used in each study [3], as well the duration of cor-
ticosteroid administration so as to cover the days
with peak AF development (2nd day and 3rd day).
Increased likelihood of wound infections and
gastrointestinal bleeding (stress ulcer) is a concernwith the use of steroids. In our study, there was no
statistical difference in the rate of major complica-
tions between the steroid and the placebo groups.
Wound infection, whether deep or superficial, did
not increase significantly upon using steroids.
Also, both groups had a similar rate of upper gas-
trointestinal bleeding. In the study by Prasong-
sukran et al. [3], there was no statistically
significant difference in major and overall compli-
cations between the steroid and placebo groups,
although there was statistically significant differ-
ence in minor complications between the two
groups. High blood sugar levels as well impaired
glucose tolerance were seen more in the steroid
group, which was also noticed in our study but
with no statistical significance. The Cochrane
analysis [22] did not find an increased risk of
infection in 15 studies including infectious compli-
cations as secondary outcome. Ali-Hassan-Sayegh
et al. [1] found in a meta-analysis of 23 random-
ized controlled trials (RCTs) that corticosteroid
therapy did not increase incidence of postopera-
tive infection with an odds ratio of 1.03 (95% con-
fidence interval: 0.68–1.5; p = 0.8) with all doses
(low, medium, high). In addition, they found in a
meta-analysis of 11 randomized controlled trials
that corticosteroid therapy did not have the ability
to reduce the incidence of postoperative myocar-
dial infarction [1], which is similar to the results
found in our study.
Regarding the length of hospital stay, no statis-
tically significant difference was found between
the treatment and control groups, which was also
seen in other studies [3]. Length of hospital stay
has been investigated in three meta-analyses
[1,22,23]. The Cochrane meta-analysis [22] found
significant reductions in hospital stay by about
half a day (95% confidence interval, 0.65–0.15).
The results of the three meta-analyses are similar,
and they all had significant heterogeneity
between studies as a result of different time-
span coverage as well as different corticosteroid
dose regimens in different risk categories of
patients [5]. Ali-Hassan-Sayegh et al. [1] found in
a meta-analysis of 35 trials that corticosteroid ther-
apy could significantly reduce length of hospital
stay.
Regarding gastrointestinal complications, since
1990 only three small studies involving a total of
204 patients have gastrointestinal bleeding as sec-
ondary outcome [3]. In the Cochrane meta-
analysis [22], these three studies showed a trend
of increased gastrointestinal bleeding in the corti-
costeroid group although significant heterogene-
ity exists between the studies [5].
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Although our study showed obvious beneficial
effects of steroids in reducing postoperative AF,
we noticed a slight increase in postoperative com-
plications with no statistical significance. There-
fore, our study was underpowered to assess the
safety of corticosteroids, which makes it essential
to undertake a larger trial to demonstrate the
superiority of corticosteroid treatment compared
with placebo in different doses. In fact, we
encountered obvious difficulties in including
other centers in the study due to the small number
of cases done there in addition to technical prob-
lems. Furthermore, we should adjust the corticos-
teroid doses (e.g., give half the dose of
methylprednisolone, 500 mg, instead of 1 g) and
more importantly use steroids for selective
patients, who are at higher risk of developing
AF, such as chronic obstructive pulmonary dis-
ease, older patients, valvular disease, and longer
cross clamp surgeries. Moreover, we can avoid
diabetic patients, especially those with uncon-
trolled blood sugar, who are potentially at risk of
infections. Further studies are needed to show
the benefits of combining steroids with other pre-
ventive measures (such as intravenous amio-
darone and magnesium) in reducing the risk of
postoperative AF after cardiac surgery.References
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